Head and Neck Cancer Treatment in India
Get Head and Neck Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Head and Neck Cancer Treatment in UAE
Head and Neck Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Head and neck cancer treatment encompasses a multidisciplinary spectrum of surgical resections, precision radiotherapy, immunotherapy, and targeted molecular therapies directed at malignancies arising in the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, salivary glands, and thyroid. With five-year survival rates ranging from 50% to over 90% depending on stage and subsite — and exceeding 85% for early-stage, HPV-positive oropharyngeal cancers — outcomes are strongly tied to institutional volume and specialist expertise. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-accredited facilities in Dubai and Abu Dhabi, delivering world-class head and neck oncology at a fraction of Western costs, with end-to-end coordination from first consultation through post-treatment surveillance.
Hospital Stay: 7–21 days (varies by modality: 7–10 days for major surgical resection; 3–5 days for concurrent chemoradiation induction; up to 3 weeks for complex reconstructive cases) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (surgical and reconstructive cases require 6–8 weeks; definitive chemoradiation patients typically cleared for international travel at 4–6 weeks post-treatment completion, subject to oncologist sign-off) • Success Rate: 50–90%+ (stage- and subsite-dependent; early-stage laryngeal and HPV-positive oropharyngeal cancers exceed 85–90% five-year survival; locally advanced disease 40–60% with multimodal therapy)
What Is It?
Head and neck cancers are a heterogeneous group of malignancies, the vast majority (>90%) being squamous cell carcinomas (HNSCC), arising from the mucosal epithelium lining the upper aerodigestive tract. Primary subsites include the oral cavity (lips, tongue, floor of mouth, buccal mucosa), oropharynx (base of tongue, tonsils, soft palate — increasingly driven by high-risk HPV-16 infection), larynx (supraglottic, glottic, subglottic), hypopharynx, nasopharynx, and major and minor salivary glands. Thyroid malignancies — papillary, follicular, medullary, and anaplastic — are categorized separately but managed within head and neck oncology programs. Risk factors include tobacco and alcohol synergy, betel nut chewing (prevalent across South and Southeast Asia), HPV infection (particularly oropharyngeal), Epstein-Barr virus (nasopharyngeal), and prior radiation exposure.
The physiological impact of head and neck cancer is uniquely devastating because the anatomical region governs speech, swallowing, breathing, mastication, and facial aesthetics — functions central to quality of life and social identity. Tumors can cause progressive dysphagia leading to malnutrition, airway compromise necessitating emergency tracheotomy, cranial nerve deficits (facial palsy, vocal cord paralysis, hypoglossal nerve involvement), and cervical lymphadenopathy with potential carotid encasement. Advanced disease may invade the skull base, orbit, or prevertebral fascia, dramatically limiting resectability. Functional preservation — maintaining the larynx, tongue mobility, and mandibular continuity — is therefore a central tenet of modern treatment planning, balanced against oncologic radicality.
The contemporary standard of care is determined by a dedicated multidisciplinary tumor board (MDT) comprising head and neck surgical oncologists, radiation oncologists, medical oncologists, radiologists, pathologists, speech-language pathologists, and maxillofacial prosthodontists. Staging per AJCC 8th Edition (incorporating separate TNM classifications for HPV-related vs. HPV-unrelated oropharyngeal cancer) drives treatment selection. Early-stage (I–II) disease is typically managed with single-modality therapy — either surgery or radiotherapy — preserving the alternative for salvage. Locally advanced (III–IVA/B) disease mandates multimodal therapy: surgery followed by adjuvant (chemo)radiation based on pathological risk features (positive margins, extranodal extension — ENE), or definitive concurrent chemoradiation (CRT) with weekly cisplatin (40 mg/m²) or high-dose cisplatin (100 mg/m² q3w) as the platinum backbone. Induction chemotherapy with TPF (docetaxel-cisplatin-5-fluorouracil) is selectively employed for organ preservation or to downstage borderline-resectable disease. Recurrent or metastatic (R/M) HNSCC is now managed with first-line pembrolizumab (anti-PD-1 immunotherapy) — alone for PD-L1 CPS ≥1, or combined with platinum-fluorouracil for all-comers — based on the KEYNOTE-048 trial, representing a paradigm shift from cetuximab-based EXTREME regimen.
Candidates
• ELIGIBLE CANDIDATES:
• Newly diagnosed head and neck squamous cell carcinoma (HNSCC) of any subsite, confirmed by endoscopic biopsy with histopathological analysis including HPV/p16 status (via IHC and/or PCR), EBV serology (nasopharyngeal), and PD-L1 Combined Positive Score (CPS)
• Patients with differentiated thyroid cancer (papillary or follicular) of any risk category, or medullary thyroid cancer with germline RET mutation analysis
• Locally advanced disease (Stage III–IVB) being evaluated for organ-preservation concurrent chemoradiation vs. primary surgical resection with reconstruction
• Recurrent or metastatic HNSCC previously treated with platinum-based therapy, now eligible for immunotherapy (pembrolizumab, nivolumab) or targeted therapy (cetuximab — anti-EGFR)
• Patients with borderline-resectable disease being considered for induction TPF chemotherapy followed by restaging
• Candidates for transoral robotic surgery (TORS) for oropharyngeal or supraglottic lesions: T1–T2 tumors with adequate mouth opening (>35 mm interincisal distance) and favorable anatomy
• Patients requiring microvascular free-flap reconstruction (radial forearm, fibular osteocutaneous, anterolateral thigh — ALT) following ablative surgery
• REQUIRED DIAGNOSTIC WORKUP:
• Contrast-enhanced MRI of the primary site (superior soft-tissue delineation for oral cavity, oropharynx, nasopharynx, skull base)
• Contrast-enhanced CT of the neck and chest (nodal staging, pulmonary metastases)
• 18F-FDG PET-CT (whole-body staging, detection of occult nodal disease, distant metastases, and synchronous primaries)
• Panendoscopy under general anesthesia (direct laryngoscopy, esophagoscopy, bronchoscopy) for primaries of unknown origin or submucosal extension assessment
• Ultrasound-guided fine needle aspiration cytology (FNAC) or core needle biopsy of cervical nodes
• Audiogram baseline (pre-cisplatin, to document pre-existing sensorineural hearing loss)
• Dental OPG and panoramic radiograph + dental clearance (mandatory pre-radiation)
• Renal function panel (eGFR ≥50 mL/min for cisplatin eligibility), CBC, LFT, thyroid function
• Swallowing evaluation: videofluoroscopic swallowing study (VFSS) or fiberoptic endoscopic evaluation of swallowing (FEES) for baseline dysphagia assessment
• Nutritional assessment (BMI, prealbumin, albumin): PEG tube or nasogastric tube planning for patients anticipated to have severe radiation-induced mucositis
• Echocardiogram (if anthracycline-based regimens considered, or cardiac history)
• RELATIVE CONTRAINDICATIONS / EXCLUSION FACTORS:
• ECOG performance status ≥3 (poor functional reserve precluding aggressive multimodal therapy)
• Severe cisplatin contraindications: eGFR <50 mL/min, grade ≥2 peripheral neuropathy, significant bilateral sensorineural hearing loss (carboplatin substitution considered)
• T4b disease with carotid encasement (>270° circumferential involvement) or prevertebral fascia fixation — unresectable by consensus definition
• Distant metastatic disease at multiple sites (systemic therapy-first approach)
• Prior head and neck radiation to the same region (re-irradiation protocols available at specialized centers but carry high toxicity risk)
• Uncontrolled comorbidities: decompensated cardiac failure (NYHA Class III–IV), active interstitial lung disease (for immunotherapy), uncontrolled autoimmune disease
Procedure
SURGICAL APPROACHES:
• Transoral Robotic Surgery (TORS): Using the da Vinci Xi or SP (single-port) robotic system, TORS enables resection of oropharyngeal (tonsil, base of tongue), supraglottic, and selected hypopharyngeal lesions through the mouth without external incisions. Advantages include three-dimensional magnified visualization, tremor-filtered wristed instrumentation, negative margin rates comparable to open surgery, dramatically reduced hospital stay (3–5 days), faster swallowing recovery, and avoidance of mandibulotomy. Indicated for T1–T2 tumors with adequate transoral access. Simultaneous ipsilateral or bilateral selective neck dissection (Levels I–IV or II–IV) is performed transcervically.
• Transoral Laser Microsurgery (TLM): CO₂ laser-based endoscopic resection via direct laryngoscopy under general anesthesia. Highly effective for early glottic (T1a, T1b, T2) and supraglottic lesions, offering laryngeal preservation with excellent voice outcomes. Tumor is resected in multiple passes with histopathologic margin assessment guiding extent.
• Open Surgical Resection: Mandibulotomy (visor flap + paramedian mandibular swing) approach for posterior oral cavity and oropharynx; lateral pharyngotomy and suprahyoid pharyngotomy for selected hypopharyngeal lesions; total laryngectomy (TL) with tracheoesophageal puncture (TEP) voice prosthesis for T3–T4 glottic/supraglottic cancers failing larynx preservation or as salvage post-CRT. Partial laryngeal procedures (supraglottic laryngectomy, vertical partial laryngectomy) are organ-preserving options for carefully selected early-to-intermediate laryngeal cancers.
• Neck Dissection: Selective neck dissection (SND) — removing at-risk nodal levels (I–III for oral cavity; II–IV for larynx/hypopharynx) — is standard for elective or therapeutic cervical nodal management. Modified radical neck dissection (MRND — preserving sternocleidomastoid, internal jugular vein, and/or accessory nerve) and radical neck dissection (RND) are reserved for extensive nodal disease.
• Microvascular Free-Flap Reconstruction: Following ablative surgery, functional and aesthetic reconstruction uses microsurgically anastomosed free tissue transfers. The fibular osteocutaneous free flap is the gold standard for mandibular reconstruction, restoring jaw continuity and enabling dental implant rehabilitation. The radial forearm fasciocutaneous free flap (RFFF) is preferred for tongue, floor-of-mouth, and pharyngeal defects due to its pliability and thin skin paddle. The anterolateral thigh (ALT) free flap is used for large composite pharyngeal and neck defects. Success rates of free-flap reconstruction exceed 95% at high-volume centers.
• Thyroid and Parathyroid Surgery: Total thyroidectomy (with or without central and lateral neck dissection) for differentiated and medullary thyroid cancer; hemithyroidectomy with intraoperative frozen section for diagnostic purposes. Intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN) is standard practice. Robotic thyroidectomy via transaxillary or retroauricular (facelift) approach offers scar-free access.
RADIATION THERAPY:
• Intensity-Modulated Radiation Therapy (IMRT): The current standard for all head and neck sites. IMRT delivers sculpted dose distributions conforming to complex three-dimensional tumor volumes while sparing critical structures — parotid glands (reducing xerostomia), spinal cord, brainstem, mandible (reducing osteoradionecrosis risk), optic apparatus, and cochlea. Delivered in 6–7 weeks (30–35 fractions) using simultaneous integrated boost (SIB) or sequential boost technique. Dose: 66–70 Gy to gross disease; 54–60 Gy to elective nodal volumes.
• Volumetric Modulated Arc Therapy (VMAT): An advanced IMRT delivery technique using rotating gantry arcs, reducing treatment time per fraction to 2–5 minutes while maintaining or improving dosimetric quality.
• Proton Beam Therapy (PBT): Available at select Indian and UAE centers, PBT exploits the Bragg peak — depositing maximum dose at a defined depth with near-zero exit dose — offering superior sparing of brainstem, spinal cord, and parotid glands. Particularly advantageous for nasopharyngeal carcinoma, skull base tumors, pediatric head and neck malignancies, and re-irradiation scenarios.
• Stereotactic Body Radiation Therapy (SBRT): High-dose, hypofractionated radiation (5 fractions over 1–2 weeks) for oligometastatic head and neck disease, reirradiation of small recurrent tumors, or as a boost to primary IMRT.
SYSTEMIC THERAPY:
• Concurrent Chemoradiation (CRT): Weekly cisplatin (40 mg/m²) or high-dose cisplatin (100 mg/m² on days 1, 22, 43) concurrent with IMRT is the standard of care for locally advanced HNSCC organ preservation or adjuvant post-surgical high-risk features (positive margins, ENE). Carboplatin-based regimens (AUC 1.5–2 weekly) are used for cisplatin-ineligible patients.
• Induction Chemotherapy (TPF Protocol): Docetaxel 75 mg/m² + Cisplatin 75 mg/m² + 5-Fluorouracil 750–1000 mg/m²/day × 4 days, every 21 days × 3 cycles. Used for larynx/hypopharynx preservation (TAX 324/TAX 323 trial evidence) or downstaging borderline-resectable disease.
• Anti-EGFR Therapy (Cetuximab): A chimeric IgG1 monoclonal antibody targeting EGFR. Used concurrent with radiotherapy (Bonner protocol) as an alternative to cisplatin in platinum-ineligible patients, or combined with platinum-fluorouracil in R/M HNSCC (EXTREME regimen). Note: KEYNOTE-048 has largely replaced EXTREME with pembrolizumab-platinum-FU in first-line R/M HNSCC.
• Immunotherapy (Checkpoint Inhibitors): Pembrolizumab (anti-PD-1, Keytruda) is FDA/EMA-approved first-line for R/M HNSCC (KEYNOTE-048) and is being investigated in the adjuvant and definitive settings. Nivolumab (Opdivo) is approved second-line post-platinum (CheckMate-141 trial). PD-L1 CPS score (assessed by 22C3 pharmDx assay) guides pembrolizumab monotherapy eligibility.
• Targeted Therapy for Thyroid Cancer: Lenvatinib (multikinase inhibitor — VEGFR1-3, FGFR1-4, PDGFR-α, RET, KIT) and sorafenib for radioiodine-refractory differentiated thyroid cancer (SELECT trial, DECISION trial). Vandetanib and cabozantinib for medullary thyroid cancer (targeting RET). Selpercatinib (RET-selective inhibitor, LIBRETTO-001) for RET-mutant/fusion-positive thyroid and other cancers — highly active with superior safety profile. Pralsetinib (BLU-667) is an alternative RET inhibitor. Vemurafenib/dabrafenib+trametinib for BRAF V600E-mutant anaplastic thyroid cancer.
• Radioiodine (I-131) Therapy: For differentiated thyroid cancer (papillary, follicular) following total thyroidectomy — ablation of thyroid remnant and treatment of metastatic iodine-avid disease. Dosing based on ATA risk stratification and post-surgical whole-body scan.
Cost of Head and Neck Cancer Treatment: India vs. UAE
The cost of head and neck cancer treatment varies significantly depending on disease stage, treatment modality (surgery alone, chemoradiation, combined multimodal therapy, immunotherapy, or reconstructive procedures), and the destination. Both India and the UAE offer internationally accredited oncology programs with cutting-edge technology — however, India delivers comparable clinical outcomes at 40–60% lower cost than the UAE, making it the leading destination globally for cost-conscious medical travelers. UAE facilities in Dubai and Abu Dhabi attract patients seeking premium hospitality standards, shorter travel distances from Europe and the Middle East, and English/Arabic-speaking care teams. GAF Healthcare provides transparent, all-inclusive package quotations for both destinations tailored to the patient's specific treatment plan.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,000 – $35,000 | ~54% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $10,000 – $75,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TREATMENT EVALUATION (Days 1–14 before treatment start):
• Day 1–3: Remote consultation with GAF Healthcare's head and neck oncology specialist. Upload all prior imaging, biopsy reports, and histopathology. MDT review initiated.
• Day 4–7: Arrival in India or UAE. Comprehensive in-person evaluation: repeat or supplementary imaging (MRI primary site, PET-CT if not recent <6 weeks), panendoscopy under GA for direct tumor assessment and mapping biopsies if needed.
• Day 8–10: Multidisciplinary tumor board presentation and consensus treatment plan. Simultaneous: dental clearance and extractions if required pre-radiation; baseline audiogram; nutritional assessment and PEG/NGT planning; speech-language pathology baseline swallowing assessment; anesthesiology pre-operative clearance.
• Day 11–14: Radiation planning CT simulation with thermoplastic immobilization mask fabrication; radiation target volume delineation (GTV, CTV, PTV) and IMRT/VMAT/proton plan optimization; dosimetric review and physics QA.
PHASE 2A — SURGICAL TREATMENT (for resectable disease; approximately Days 14–35):
• Day 14 (Surgery Day): Major ablative surgery + neck dissection + microvascular free-flap reconstruction performed under general anesthesia. Duration: 6–16 hours for complex reconstructive cases. Patient admitted to head and neck surgical ICU post-operatively.
• Day 1–3 post-op: ICU monitoring — free-flap perfusion checks every 1–2 hours (clinical + Doppler), airway management (temporary tracheotomy tube in situ for major oral/pharyngeal resections), wound drains, NG tube feeding.
• Day 3–5 post-op: Transfer to surgical ward. Drain removal when output <30 mL/24h. Tracheotomy downsizing initiated. Early physiotherapy.
• Day 7–10 post-op: VFSS swallowing assessment. Initiation of oral intake if safe (modified texture diet). Tracheotomy decannulation if airway maintained.
• Day 10–14 post-op: Wound healing assessment. Surgical histopathology result review — confirmation of margins, ENE status — determining adjuvant therapy plan. Discharge planning.
• Day 14–21: Hospital discharge. Outpatient wound review, diet advancement, swallowing therapy.
PHASE 2B — DEFINITIVE CHEMORADIATION (for organ preservation or unresectable disease; ~7 weeks):
• Week 1: First cisplatin cycle administered. IMRT/VMAT commences (first of 33–35 fractions, 5 days/week).
• Weeks 1–7: Daily IMRT treatment sessions (~15–20 minutes per session including setup). Weekly oncology review — toxicity assessment, nutritional support, pain management (opioid ladder as needed), mucositis care (magic mouthwash, sodium bicarbonate rinses), and anti-emetic management.
• Week 3–4: Significant mucositis (Grade 2–3) and odynophagia expected. NG tube or PEG feeding initiated if oral intake <60% of caloric requirements. Skin reactions (brisk erythema, dry/moist desquamation in exit fields) managed with barrier creams.
• Week 6–7: Completion of cisplatin cycles (2nd or 3rd depending on schedule). Final radiation fraction delivered. Comprehensive end-of-treatment assessment.
PHASE 3 — EARLY RECOVERY & RESPONSE ASSESSMENT (Weeks 7–12 post-treatment):
• Week 8–10: First post-treatment imaging. PET-CT at 12 weeks post-CRT (standard Neck Imaging Reporting and Data System — NI-RADS guideline) to assess nodal response — a complete metabolic response avoids planned neck dissection.
• Week 10–12: Resolution of acute toxicities: mucositis typically heals by 6–8 weeks; xerostomia (dry mouth) is persistent due to parotid irradiation and managed with salivary substitutes, pilocarpine, and acupuncture. Dysphagia rehabilitation with progressive swallowing exercises (Shaker exercises, Mendelsohn maneuver) continues.
• FIT-TO-FLY MILESTONE: Surgical patients — typically 6–8 weeks post-operatively, once wound healing is complete, tracheotomy decannulated, and oral nutrition re-established. CRT patients — typically 4–6 weeks after completing radiation, once acute mucositis has resolved and the oncologist confirms stable hematological parameters. Clearance is individualized.
PHASE 4 — SURVEILLANCE (Months 3–60, with remote follow-up via GAF Healthcare telemedicine):
• Months 1–2: Clinical review every 4 weeks. TSH monitoring post-thyroidectomy or after neck radiation (high rate of hypothyroidism).
• Months 3–12: Clinical examination every 2–3 months. Laryngoscopy/nasendoscopy at each visit. PET-CT or MRI at 6 and 12 months.
• Years 2–5: Clinical review every 6 months. Annual imaging per institutional protocol.
• Speech, swallowing, and shoulder rehabilitation (post-neck dissection — accessory nerve monitoring) continue throughout the surveillance period via GAF Healthcare's telerehabilitation network.
Risks & Considerations
Head and neck cancer treatment carries a specific and substantial risk profile that patients must understand before committing to therapy. Surgical risks include free-flap failure (partial or total — occurring in 3–8% of cases even at expert centers), requiring urgent return to the operating room; fistula formation (orocutaneous or pharyngocutaneous) particularly in previously irradiated fields or malnourished patients; wound infection and dehiscence; injury to the facial nerve (VII), hypoglossal nerve (XII), accessory nerve (XI — causing shoulder dysfunction), or recurrent laryngeal nerve (RLN — permanent voice change or aspiration); and carotid artery injury in the setting of radical neck dissection for fixed nodal disease. Tracheotomy-related complications (tube dislodgement, stomal granulation, tracheomalacia) are relevant for laryngectomized patients. Chemoradiation-specific toxicities include severe oral mucositis (Grade 3–4 in 30–60% of patients receiving standard CRT) with resultant odynophagia, dehydration, and nutritional failure requiring enteral feeding; permanent xerostomia (parotid-sparing IMRT reduces but does not eliminate this risk); osteoradionecrosis (ORN) of the mandible — a serious late complication occurring in 2–10% of patients, risk factors including tooth extraction in an irradiated field, smoking, and high radiation dose; radiation-induced dysphagia and aspiration — a major late toxicity affecting swallowing musculature, potentially leading to aspiration pneumonia; hypothyroidism in 30–50% of patients receiving neck irradiation; carotid stenosis (late, >5 years) and increased cerebrovascular risk; and secondary malignancies (rare, long-term). Cisplatin-specific risks include nephrotoxicity (managed with aggressive hydration and magnesium supplementation), ototoxicity (irreversible high-frequency sensorineural hearing loss — cumulative dose-dependent, requiring baseline and serial audiometry), neuropathy, and myelosuppression. Immunotherapy with pembrolizumab or nivolumab carries immune-related adverse event (irAE) risks — immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency, hypophysitis), and rare myocarditis — requiring vigilant monitoring and prompt corticosteroid management. All risks are carefully mitigated through pre-treatment optimization, high-volume experienced surgical teams, IMRT-based organ-sparing radiation planning, and proactive supportive care protocols at GAF Healthcare partner institutions.
Top Hospitals for Head and Neck Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Head and Neck Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. P Subramanya Rao
MBBS, DLO, DNB
Head & Neck Surgical Oncologist
Apollo Hospitals, Bannerghatta Road, Bengaluru, India
22+ Yearsof experience
Dr. P Subramanya Rao is a distinguished Senior Consultant in Surgical Oncology with over 22 years of specialized expertise in head and neck cancer surgery. Based at Apollo Hospitals, Bannerghatta Road in Bengaluru, he holds an MBBS, Diploma in Laryngology and Otology (DLO), and is a Diplomate of the National Board (DNB) in ENT Oncology, establishing a strong foundation in both general surgery and oncological principles. Dr. Rao specializes in complex… Read more
Dr. Karan Gupta
MBBS, MS in Otolaryngology & Head-Neck Surgery, DNB, Fellowship in Robotic Head-Neck Surgery, Fellowship in Head-Neck Surgery, Fellowship in Head-Neck and Reconstructive Surgery
Head & Neck Surgical Oncologist
Medanta - The Medicity, Gurugram, India
15+ Yearsof experience
Dr. Karan Gupta is a Senior Consultant in Surgical Oncology and a specialist in Head & Neck Cancer Surgery with 15 years of focused clinical experience. He earned his MBBS with a Gold Medal from Maulana Azad Medical College, Delhi, and his MS in Otolaryngology & Head-Neck Surgery with a Gold Medal from PGIMER, Chandigarh, two of India's most respected medical institutions. His advanced surgical oncology training reflects a commitment to excellence across… Read more
Dr. Deepak Sarin
MBBS, MS (Otolaryngology) — Gold Medal, DNB (Otolaryngology), Fellowship in Head & Neck Oncology
Head & Neck Oncology Surgeon
Medanta - The Medicity, Gurgaon, India
27+ Yearsof experience
Dr. Deepak Sarin is a senior head and neck oncology surgeon with over 20 years of clinical experience. He serves as Vice Chairman — Head & Neck Cancer, Thyroid & Parathyroid Surgery at Medanta – The Medicity, Gurgaon. Trained as a clinical fellow in Head & Neck Ablative and Reconstructive Surgery at the Sylvester Comprehensive Cancer Center, University of Miami, USA, Dr. Sarin has been instrumental in setting up dedicated head and neck cancer departments… Read more
Dr. Anil K D'Cruz
MBBS, MS, DNB, FRCS (Hon.)
Head & Neck Surgical Oncologist
Apollo Athenaa Women's Cancer Centre, Chennai, India
33+ Yearsof experience
Dr. Anil K D'Cruz is a Senior Consultant in Surgical Oncology with more than 33 years of distinguished clinical experience in the diagnosis and surgical management of head and neck malignancies. He holds the prestigious Fellowship of the Royal College of Surgeons (Hon.) from London and has served as President Elect and President of the Union International for Cancer Control (UICC), making him the first Indian to hold this honour. His credentials reflect a… Read more
Dr. Abhishek Budharapu
MBBS, MS, MCh, MRCS, DNB
Head & Neck Surgical Oncologist
Apollo Hospital, Jubilee Hills, Hyderabad, India
11+ Yearsof experience
Dr. Abhishek Budharapu is a Consultant Surgical Oncologist specializing in Head & Neck Surgical Oncology at Apollo Hospital, Jubilee Hills, Hyderabad. With more than 11 years of clinical experience, he has established himself as a trusted specialist in the diagnosis and surgical management of head and neck malignancies. His academic credentials include an MCh from Kidwai Memorial Institute of Oncology in Bangalore, combined with membership in the Royal… Read more
Frequently Asked Questions — Head and Neck Cancer Treatment
The cost of head and neck cancer treatment varies considerably based on disease stage, subsite, and the specific treatment protocol — whether that involves surgery alone, definitive chemoradiation, combined multimodal therapy with reconstruction, or immunotherapy with agents such as pembrolizumab. In India, at JCI- and NABH-accredited oncology centers in cities such as Mumbai, Delhi, Chennai, and Bengaluru, the total treatment cost typically ranges from $4,000 to $35,000 USD. A straightforward early-stage surgical procedure (e.g., transoral robotic surgery for T1 oropharyngeal cancer plus selective neck dissection, with 5–7 days of hospitalization) falls in the $4,000–$10,000 range. A complex case requiring total laryngectomy, bilateral neck dissection, and pectoralis major myocutaneous flap reconstruction with 14–21 days of inpatient care may reach $15,000–$25,000. Full-course concurrent chemoradiation (35 fractions of IMRT + 6–7 weekly cisplatin cycles + supportive care over 7 weeks) runs approximately $8,000–$18,000. Immunotherapy with pembrolizumab, if required for recurrent/metastatic disease, adds $3,000–$7,000 per cycle and is typically not included in surgery-based package estimates. In the UAE, at JCI- and DHA-accredited institutions in Dubai (such as Mediclinic City Hospital, American Hospital Dubai, King's College Hospital Dubai) and Abu Dhabi (Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City), comparable treatment costs range from $10,000 to $75,000 USD. The significant premium reflects higher facility costs, physician fees structured on Western benchmarks, luxury private room standards, and the overall cost of operating in a high-income economy. An equivalent transoral robotic surgery case may cost $12,000–$22,000 in Dubai; a full course of chemoradiation runs $20,000–$40,000; and complex surgical reconstruction with extended hospitalization can reach $50,000–$75,000. In summary, India is consistently 40–60% less expensive than the UAE for equivalent oncology procedures, making it the most cost-efficient destination globally for head and neck cancer treatment without compromise in clinical outcomes. GAF Healthcare provides a no-obligation, itemized cost estimate for your specific diagnosis and treatment plan within 48 hours of receiving your medical reports.
The minimum safe in-country stay before international air travel — what oncologists refer to as 'fit-to-fly' clearance — depends critically on which treatment modality you undergo, and is always determined on an individual basis by your treating team. For patients undergoing SURGICAL TREATMENT (e.g., transoral robotic surgery, open resection with neck dissection, or major ablative surgery with free-flap microvascular reconstruction): Simple transoral surgical cases with minimal reconstruction typically require 3–4 weeks in-country before flying (approximately 2–3 weeks post-operatively, allowing wound healing confirmation and swallowing rehabilitation initiation). Complex cases involving total laryngectomy, fibular free-flap mandibular reconstruction, or pharyngeal reconstruction require a minimum of 6–8 weeks in-country. This extended stay ensures: complete wound healing and absence of fistula; successful tracheotomy decannulation (where applicable); establishment of safe oral or enteral feeding; removal of all drains and sutures; and post-operative histopathology review to finalize the adjuvant therapy plan. Patients with tracheostomies (permanent stomas post-total laryngectomy) may fly when stoma care is self-sufficient and cabin pressure concerns have been reviewed — typically after 6–8 weeks. For patients undergoing DEFINITIVE CONCURRENT CHEMORADIATION (7 weeks of daily IMRT + weekly cisplatin): Treatment itself lasts approximately 7 weeks (35 fractions). Following the last radiation fraction, patients are generally advised to remain in-country for a further 3–5 weeks — a total in-country stay of approximately 10–12 weeks. This post-radiation period is necessary for: resolution of Grade 3 oral mucositis (typically heals within 4–6 weeks post-radiation completion); nutritional rehabilitation and removal of nasogastric tube or PEG; renal function and hematological recovery post-cisplatin; the 12-week PET-CT response assessment (per NI-RADS guidelines), which determines whether a planned neck dissection is required; and oncologist confirmation that you are medically stable for travel. For patients receiving IMMUNOTHERAPY (pembrolizumab): If ongoing IV immunotherapy cycles are required (administered every 3 weeks), these can frequently be continued at a partnered oncology center in your home country after GAF Healthcare facilitates medical records transfer and treatment handover. Fitness to fly between cycles is generally achievable 7–10 days after each infusion if no significant immune-related adverse events (irAEs) have occurred. As a general planning benchmark, international patients and their families should budget for a total in-country stay of 4–6 weeks (surgical cases, minimal reconstruction) to 12–14 weeks (combined chemoradiation with response assessment). GAF Healthcare's medical coordinators work directly with your treating oncologist to issue a formal fit-to-fly certificate with specific recommendations regarding cabin pressure, oxygen supplementation, deep-vein thrombosis prophylaxis, and travel medications before you depart.
The success rate of head and neck cancer treatment — most meaningfully expressed as five-year overall survival (OS) — is highly variable and depends on four key factors: anatomical subsite of the primary tumor, clinical stage at diagnosis (per AJCC 8th Edition TNM), HPV/p16 status (for oropharyngeal cancers), and the volume and expertise of the treating institution. Here is a clinically realistic breakdown by subsite and stage: OROPHARYNGEAL CANCER (HPV-positive, p16+): This is now the most favorable subtype. Five-year OS for Stage I–II HPV-positive oropharyngeal cancer exceeds 85–90%. Even Stage III disease achieves 70–80% five-year OS with concurrent chemoradiation. HPV-positive disease has a fundamentally better prognosis than HPV-negative HNSCC due to superior radiosensitivity, which is why AJCC 8th Edition introduced a separate, less aggressive staging system for this subtype. De-escalation trials (OPTIMA, ECOG-ACRIN 3311, MC1273) are actively investigating reduced-intensity CRT to preserve these excellent outcomes while reducing long-term toxicity. ORAL CAVITY CANCER: Five-year OS ranges from approximately 80–90% for Stage I, 60–75% for Stage II, 40–55% for Stage III, and 20–35% for Stage IVA disease. Negative surgical margins and absence of extranodal extension (ENE) are the strongest predictors of cure. LARYNGEAL CANCER: Early-stage (T1 glottic) laryngeal cancer — often treated with transoral laser microsurgery or radiotherapy — has a five-year local control and disease-specific survival rate exceeding 90–95%. T2 disease achieves 70–80% five-year OS. Locally advanced (T3–T4) laryngeal cancer treated with organ-preservation CRT achieves 50–65% five-year OS, with laryngeal preservation in approximately 70–80% of those who survive. NASOPHARYNGEAL CANCER: Highly radiosensitive, nasopharyngeal carcinoma treated with definitive CRT (cisplatin + IMRT ± induction/adjuvant chemotherapy) achieves five-year OS rates of 80–90% for Stage I–II and 60–70% for Stage III–IVA, reflecting the effectiveness of platinum-based CRT in this EBV-driven malignancy. THYROID CANCER: Papillary thyroid cancer — the most common thyroid malignancy — has a ten-year disease-specific survival exceeding 98% for low-risk disease (ATA low-risk category). Even high-risk differentiated thyroid cancer achieves five-year OS of 60–80% with total thyroidectomy, radioiodine ablation, and TSH suppression. Medullary thyroid cancer has a five-year OS of approximately 70–90% for localized disease. Anaplastic thyroid cancer remains the most aggressive solid tumor in oncology, with median OS of 5–6 months even with multimodal therapy, though BRAF V600E-mutant cases respond to dabrafenib+trametinib with dramatically improved outcomes. RECURRENT/METASTATIC HNSCC: First-line pembrolizumab (for PD-L1 CPS ≥1, KEYNOTE-048) achieves a median OS of 13 months as monotherapy and up to 13.6 months in combination with chemotherapy — a meaningful improvement over the historic 10.1-month median OS with the EXTREME cetuximab-based regimen. At GAF Healthcare's partner institutions — all high-volume JCI- or NABH/DHA-accredited head and neck oncology programs — free-flap reconstruction success rates exceed 95%, TORS negative margin rates are comparable to international benchmarks (>85% R0 resection), and IMRT planning adheres to QUANTEC and RTOG dose constraint guidelines. Institutional volume is one of the strongest independent predictors of survival in head and neck oncology, and our partner hospitals perform hundreds of head and neck cancer procedures annually.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive, seamlessly coordinated end-to-end logistics for international patients traveling to India or the UAE for head and neck cancer treatment, removing all administrative and non-clinical burdens so patients can focus entirely on recovery.
MEDICAL VISA ASSISTANCE — INDIA: GAF Healthcare assists patients in obtaining the Indian e-Medical Visa (e-MV), which is available to nationals of 156+ eligible countries via the online IVFRT portal. The e-MV is issued within 72 hours of application in most cases, is valid for 60 days (triple entry), and permits one accompanying attendant on an e-Medical Attendant Visa. Our team prepares the complete application package: hospital appointment letter on letterhead from the partner institution, supporting diagnostic documents, and guidance on financial documentation. For patients requiring longer stays (beyond 60 days, e.g., for 7-week CRT courses), GAF Healthcare coordinates Foreigners Regional Registration Office (FRRO) extensions directly through the hospital's international patient services desk.
MEDICAL ENTRY — UAE (DUBAI / ABU DHABI): Most nationalities receive a visa-on-arrival or visa-free access to the UAE for 30–90 days (GCC nationals, EU, UK, US, Canada, Australia, and many Asian passport holders). Nationals requiring advance visas receive full support from GAF Healthcare's UAE operations team, including DHA-registered hospital invitation letters. Dubai's proximity to Europe, the Middle East, Africa, and Central Asia — with direct flights from over 240 destinations via Emirates and flydubai — makes it logistically convenient for a wide patient catchment.
AIRPORT TRANSFERS: Dedicated, fully air-conditioned private vehicle transfers are arranged for the patient and up to two attendants from the airport to the partner hospital or recovery accommodation, and for all inter-facility transfers during the treatment course. For laryngectomized patients or those with active tracheotomies, medically equipped transfer vehicles with trained escorts are available.
DEDICATED MULTILINGUAL PATIENT COORDINATORS: Each patient is assigned a personal GAF Healthcare coordinator fluent in their language (English, Arabic, Russian, Swahili, Bangla, Pashto, and more) who serves as the single point of contact from inquiry through post-discharge follow-up. Coordinators accompany patients to key appointments, facilitate communication with the treating team, and provide real-time translation during consultations.
ACCOMMODATION FOR PATIENTS AND ATTENDANTS: For patients not admitted to the hospital, or for the attendant traveling with an admitted patient, GAF Healthcare negotiates preferential rates at partner serviced apartments and hotels within 1–3 km of the treatment facility. Properties are selected for cleanliness, accessible cooking facilities (for dietary compliance post-treatment), proximity to pharmacies, and reliable internet for telemedicine follow-up. Attendant accommodation within hospital family rooms is coordinated directly with the hospital's international services department.
TELEMEDICINE POST-DEPARTURE FOLLOW-UP: Following departure, all surveillance imaging and laboratory reports are reviewed remotely by the treating oncologist via GAF Healthcare's secure telemedicine portal, with structured video consultations at 1 month, 3 months, and 6 months post-treatment — ensuring continuity of care without unnecessary return travel.
Patients Also Explore
Other treatments commonly sought by patients considering Head and Neck Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology